RxDoctor Payments Data

Grahame Fitz, MD

Family Medicine · Latham, NYNPI 1215929377

Payments from drug & device makers

$9,346in general payments, 2019–2025

Across 593 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$787
  • AbbVie$714
  • Boehringer Ingelheim$682
  • GSK$653
  • Merck$430
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,316100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,346 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$72,192
Medicare patients
182
Services billed
1,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$71,182
EliquisApixaban66$65,813
FarxigaDapagliflozin Propanediol32$49,682
RybelsusSemaglutide35$47,302
TrulicityDulaglutide22$25,618
JanuviaSitagliptin Phosphate27$22,785
Repatha SureclickEvolocumab12$17,978
MounjaroTirzepatide11$11,501
JardianceEmpagliflozin12$11,418
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,392
Testosterone11$2,715
Levothyroxine Sodium168$2,545
Atorvastatin Calcium230$2,543
Rosuvastatin Calcium200$2,456
Losartan Potassium171$2,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,538$118,48474 claims
PfizerEliquis$388$65,81366 claims
AstraZenecaFarxiga$787$49,68232 claims
Lilly USA, LLCTrulicity, Mounjaro$410$37,11933 claims
MerckJanuvia$430$22,78527 claims
Boehringer IngelheimJardiance$682$11,41812 claims
AbbVieSynthroid$714$1,58631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Latham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →